239 results about "Nicotinamide mononucleotide" patented technology

The invention relates to the technical field of biomarkers, in particular to a blood biomarker combination for prediction and auxiliary diagnosis of ovarian reserve hypofunction (DOR), a corresponding detection kit and application of the blood biomarker combination. According to the invention, the content change of the nicotinamide mononucleotide (NMN) and the metabolite combination thereof in serum or plasma is screened for the first time and can be used as a detection index for predicting the ovarian reserve function decline. Based on the biomarker combination, the invention further provides an in-vitro detection kit containing a related standard substance, an internal standard solution and an extracting solution, and a data analysis method combined with a random forest model, so that an individual with a normal ovarian reserve function and an individual with hypofunction can be accurately distinguished. The method is noninvasive, simple, convenient, high in sensitivity and suitable for early recognition and layered screening of clinical ovarian reserve hypofunction.

The invention provides anti-aging moisturizing essence and a preparation method thereof, and belongs to the technical field of cosmetics. The essence is prepared from a plant extract, sodium pyrrolidone carboxylate, hexapeptide, nicotinamide mononucleotide, vitamin B5, galactose yeast fermentation product filtrate, b-glucan, sodium hyaluronate, glycerol, tranexamic acid, blue copper peptide, arbutin, nicotinamide, vitrin, a bifidus yeast fermentation product, a bifidus yeast fermentation lysate and the like. Wherein the plant extract is prepared by mixing rosemary, frankincense resin, tea flowers, sandalwood and jasmine flowers through ultrasonic extraction, comprehensive skin care is achieved from multiple angles of anti-aging, whitening, moisturizing and repairing, the overall health of the skin is guaranteed, and the skin care cream is suitable for various skin types.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The invention relates to a natural plant functional component based on cell function regulation, a natural plant composition and application thereof. The natural plant composition is prepared from the following raw material components in parts by weight: 1000 to 1600 parts of phospholipid, 200 to 400 parts of cholesterol, 200 to 400 parts of prinsepia utilis royle oil, 100 to 300 parts of ergothioneine and 200 to 500 parts of nicotinamide mononucleotide. Compared with the prior art, the composition not only can cover multi-target composite components with ROS removal, mitochondrial autophagy activation and NAD + level improvement, but also can improve the component permeability by optimizing the delivery technology, thereby effectively improving the skin anti-aging effect and the like.

The invention relates to a compound NMNH calcium salt, in particular to an amorphous form of a reduced β-nicotinamide mononucleotide calcium salt, a preparation method therefor, a use thereof as a pharmaceutical ingredient, a health care product ingredient and a cosmetic ingredient or as a food additive, and a formulation containing the salt, belonging to the field of medicines, health care products, cosmetics and food additives. Specifically, described in the invention is a NMNH calcium salt amorphous compound. The compound shows long-term continuous stability, and compared with NMNH disodium salt, has significantly superior oxidation resistance and stability, and anti-hygroscopic properties, and is more beneficial to long-term 10 storage, promotion and market application. The NMNH calcium salt amorphous compound is simple in preparation process, easy to control and suitable for large-scale production.

The invention discloses a targeted energy metabolism composition for improving the anti-aging effect of skin as well as a preparation method and application of the targeted energy metabolism composition. The targeted energy metabolism composition is prepared from the following components in parts by mass: 0.1 to 5 parts of saccharomycetes rice fermentation filtrate, 0.1 to 5 parts of a tremella aurantialba sporocarp extract and 0.01 to 5 parts of nicotinamide mononucleotide NMN liposome. According to the targeted energy metabolism composition for improving the anti-aging effect of the skin and the preparation method and application of the targeted energy metabolism composition, effective permeation and precise delivery of functional components can be achieved, and the anti-aging, whitening and moisturizing effects of the skin are improved.

The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.

The invention relates to the technical field of pharmaceutical preparations, and discloses a biological beauty skin care product containing nicotinamide adenine dinucleotide (NAD < + >) and cell exosomes, and the biological beauty skin care product comprises the following components by weight: 10-50 parts of a pH responsive nicotinamide mononucleotide liposome; 1 to 10 parts of cell exosome sustained release microspheres; 0.1 to 2 parts of ergothioneine; 0.1 to 1 part of copper peptide; 1 to 10 parts of phytosphingosine; 0.01 to 0.5 part of water-soluble fullerene; 1-8 parts of 1, 2-pentanediol as a transdermal enhancer; 0.05 to 0.5 part of acetylated polypeptide-8; wherein the particle size of the pH response type nano-liposome is 50-200 nm, and the particle size of the hyaluronic acid microspheres is 100-500 nm, so that the skin health is promoted, and the metabolic function is regulated.

The invention discloses a method for detecting the content of nicotinamide mononucleotide, ergothioneine and nicotinamide. According to the method, the content of nicotinamide mononucleotide, ergothioneine and nicotinamide in a sample is analyzed by adopting a high performance liquid chromatography; according to the method, a CAPCELL PAK ADME chromatographic column is used, and the molecular weight of the CAPCELL PAK ADME chromatographic column is 100 And an acetonitrile-buffer solution is used as a mobile phase. Chromatographic peaks obtained by the method are sharp and symmetrical in shape, good in area reproducibility, good in separation degree, simple, rapid, high in specificity, short in detection period and high in sensitivity; the contents of nicotinamide mononucleotide, ergothioneine and nicotinamide in a sample can be rapidly, efficiently, accurately and simultaneously detected.

The utility model discloses a raw material oscillation device for beta-nicotinamide mononucleotide production, and belongs to the technical field of beta-nicotinamide mononucleotide production. The raw material oscillation device for beta-nicotinamide mononucleotide production comprises an oscillation base and an oscillation platform, a fixing plate is arranged in the oscillation base, a driving motor is installed below the fixing plate, the output end of the driving motor is connected with a hexagonal shaft, the hexagonal shaft is sleeved with a rotating disc, and a first wave face is arranged on the lower surface of the rotating disc. According to the raw material oscillation device for beta-nicotinamide mononucleotide production, the driving motor controls the rotating disc to rotate, under the action of the first wave surface, the second wave surface, the first limiting ball and the second limiting ball, vertical vibration and multidirectional inclined superposition are achieved, jolting and swinging composite motion is formed, the actually measured mixing uniformity is improved, and the production efficiency is improved. The wave crest number of the first wave surface is integral multiples of the number of the first limiting balls, so that the vertical vibration synchronism is ensured.

The present invention discloses the use of a nonspecific 5'-nucleotidase in the preparation of nicotinamide riboside. The nonspecific 5'-nucleotidase is selected from a nonspecific 5'-nucleotidase derived from Shewanella sp. HN-41. The nonspecific 5'-nucleotidase of the present invention can efficiently catalyze the hydrolysis of high-concentration nicotinamide mononucleotide (NMN) to produce nicotinamide riboside (NR), exhibits high enzymatic activity, and has value for industrial application.

The invention relates to an anti-aging capsule compounded by PQQ and mitochondrial nutrients, and discloses an anti-aging capsule which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion and supplementing high-purity raw materials and slow-release dosage forms to realize energy metabolism activation and anti-oxidation synergistic intervention. Therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The capsule is characterized by comprising the following components in parts by weight: 1-20 mg of pyrroloquinoline quinone disodium salt (PQQ), 20-100 mg of coenzyme Q10, 50-200 mg of L-carnitine tartrate, 10-100 mg of alpha-lipoic acid, 50-300 mg of nicotinamide mononucleotide (NMN) or nicotinamide nucleoside (NR), and 10-50 [mu] g of selenoprotein or organic selenium yeast, and a capsule carrier comprises 100 mg of gelatin or a plant-derived capsule shell, 180 mg of microcrystalline cellulose, 5 mg of magnesium stearate and 5 mg of silicon dioxide.

The present application relates to a preservative-free anti-aging soothing composition containing high mountain plant extract and multiple fermentation filtrate, belonging to the technical field of cosmetics. The composition comprises high mountain plant extract complex, multiple fermentation filtrate, anti-aging active and vegetable oil. The organic acids in the multiple fermentation filtrate form a natural buffer system, maintaining a weakly acidic environment to inhibit microbial growth; at the same time, the natural components in the fermentation filtrate provide protection for nicotinamide mononucleotide and ergothioneine, delaying their degradation. The present application does not need to add additional preservatives, and has the functions of anti-aging, soothing and self-preserving.

The invention discloses application of beta-nicotinamide mononucleotide in regulation and control of gene editing efficiency, belongs to the field of gene editing treatment, and finds that the beta-nicotinamide mononucleotide (NMN) can efficiently inhibit the activity of CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13 systems in a broad-spectrum manner for the first time. The application comprises emergency blocking of off-target effect in gene editing clinical treatment, biological safety prevention and control of a virus vector gene editing system, and CRISPR activity regulation and control of in-vitro non-diagnostic purpose. Experiments show that NMN can inhibit CRISPR-mediated gene damage and cell death in a cell model, the inhibition efficiency in an in-vitro enzyme digestion system reaches 68.7%, and cell growth or transfection efficiency is not affected. The invention provides an innovative solution for safe application of CRISPR (clustered regularly interspaced short palindromic repeats) technology, and the NMN is approved to be taken orally as a health care product, so that the NMN has extremely strong clinical application potential. Compared with the existing CRISPR (clustered regularly interspaced short palindromic repeats)-resistant protein or synthetic small-molecule inhibitor, the NMN has the advantages of endogenous property, high biocompatibility, good oral safety and the like.

The present application relates to the technical field of biological medicine, and in particular to a cat triple vaccine immune adjuvant containing two kinds of cat interleukins and metabolic regulatory molecules, a composition and application. The composition comprises cat interleukin 15, cat interleukin 23 and a metabolic regulatory molecule, the metabolic regulatory molecule comprises beta-nicotinamide mononucleotide, beta-nicotinamide adenine dinucleotide disodium salt, N-acetyl cysteine and L-carnitine, and can be used for preparing a cat triple vaccine or an auxiliary preparation of the cat triple vaccine. The composition can effectively improve the protection of the vaccine, prolong the protection time of the vaccine and reduce adverse reactions; the vaccine can more durably and at a higher level reduce or control the reproductive infection of viruses, significantly improve the specific humoral immune level and memory response ability of animals, and better resist the invasion and spread of FPV, FCV and FHV-1.

The present invention relates to a compound, NMNH calcium salt, and more particularly to an amorphous reduced β-nicotinamide mononucleotide calcium salt, its preparation method, its use as pharmaceutical and cosmetic ingredients, and preparations containing these salts, belonging to the fields of medicine and cosmetics. Specifically, the present invention describes an amorphous NMNH calcium salt compound that exhibits long-term stability, significantly superior antioxidant properties, stability, and hygroscopic resistance to the disodium NMNH salt, and is more suitable for long-term storage and market promotion. The amorphous NMNH calcium salt compound has a simple preparation process, is easily controlled, and is suitable for large-scale production.

The present invention addresses the problem of defining physiological significance and functions such as the influence of nicotinamide mononucleotide (NMN) contained in breast milk on the development of children. A composition for improving the athletic ability of a child is provided comprising a precursor of NAD. The improvement in athletic ability is preferably any one selected from the group consisting of promotion of skeletal muscle development and improvement in activity. A composition for reducing triglyceride levels in the blood of a child is provided comprising a precursor of NAD. A composition for reducing the blood glucose level in a child is provided comprising a precursor of NAD. A composition for inhibiting fat accumulation in children is provided, comprising a precursor of NAD.

The invention relates to the technical field of medical supplies, and particularly provides an NMN-containing circulation promoting and skin aging resisting repair patch which comprises a repair liquid and a non-woven fabric, the repairing liquid is prepared from the following raw materials in percentage by weight: 0.2 to 0.5 percent of sodium hyaluronate, 0.01 to 0.2 percent of beta-nicotinamide mononucleotide (NMN), 2 to 4 percent of glycerol, 0.5 to 1.5 percent of propylene glycol, 0.005 to 0.015 percent of ethylene diamine tetraacetic acid disodium salt, 0.015 to 0.03 percent of ethylparaben, 1 to 2 percent of sodium carboxymethyl cellulose, 0.05 to 2.0 percent of triethanolamine and the balance of purified water. The repair patch has good moisture retention, stability and oxygen permeability, and is small in irritation.

An object of the present disclosure is to provide a novel animal nutritional composition. The disclosure is directed to a racehorse nutritional composition, an animal nutritional composition for reducing an elevation of blood lactic acid concentrations, and an animal nutritional composition for coat improvement, each of which contains nicotinamide mononucleotide.

The present invention provides a strain of Escherichia coli resistant to nicotinamide stress and its application, which belongs to the field of microbial engineering technology. The strain is Escherichia coli AE74, which has been deposited in the China Center for Type Culture Collection on December 23, 2022, with a deposit number of CCTCC NO: M 20222059. The strain resistant to nicotinamide (NAM) stress has both excellent anti-nicotinamide performance and high nicotinamide mononucleotide (NMN) yield. On the one hand, under non-nicotinamide stress conditions, strain AE74 has a higher NMN yield than the starting strain. On the other hand, strain AE74 overcomes the problem of low NAM tolerance of the starting strain, and can maintain a high survival rate and NMN yield at high NAM concentrations, providing a new strain with high NMN yield suitable for industrial production.

The present invention comprises (i) or (ii). (i) Golden oyster mushroom or a processed product thereof. (ii) Nicotinamide mononucleotide and 5-deazaflavin.

The present invention relates to nicotinamide mononucleotide derivatives of Formula (I)for use in the treatment and / or prevention of a blood disorder, especially sickle cell disease. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and / or prevention of a red blood cell disorder, especially sickle cell disease.

The present invention relates to a freeze-dried injectable formulation comprising beta-nicotinamide mononucleotide, an injectable composition comprising same, and a preparation method therefor. In addition, the present invention relates to a pain relief injectable composition and a preparation method therefor, the composition comprising beta-nicotinamide mononucleotide and hyaluronidase, and having a pH of greater than 4 and 8 or less.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving senescence of a skeletal muscle system and application of the pharmaceutical composition. The pharmaceutical composition is composed of nicotinamide mononucleotide and apigenin. The composition has the advantages of being high in safety and easy to obtain, can synergistically promote cartilage, bone and muscle cell differentiation, delay cartilage degeneration and relieve bone and muscle loss, and has a good effect and application potential in the aspect of treating skeleton and muscle aging.

The invention provides a VniNatt enzyme mutant, nucleic acid, a carrier or a host cell, and application of the VniNatt enzyme mutant, nucleic acid, a carrier or a host cell in fermentation production of NMN. Compared with a wild type, the mutant can catalytically produce NMN with higher efficiency, and has good thermal stability. BL21 engineering bacteria are constructed on the basis of the VniNamt enzyme mutant and are used for producing NMN through fermentation, and the yield of the NMN can reach 54 g / L by adopting a fed-batch fermentation process.

The present application relates to a kind of compound NMNH calcium salt, especially to a kind of reduced beta-nicotinamide mononucleotide calcium salt Polymorph and its preparation method, and they are used as pharmaceutical ingredients, health product ingredients, cosmetic ingredients or as food additive, and preparation containing these salts, belong to medicine, health product, cosmetic, food additive field.The specific, the present application describes NMNH calcium salt Polymorph, the crystal shows long-term sustained stability, significantly better than the stability of NMNH disodium salt, anti-hygroscopicity, more conducive to long-term storage, popularization and marketing.The NMNH calcium salt crystal preparation process is simple, easy to control, suitable for large-scale production.

The present application relates to a new crystal form of beta nicotinamide mononucleotide shown in formula (I) and a preparation method thereof. The method of the present application does not use toxic and harmful organic solvents such as methanol, is simple to operate, is safe to production personnel, and is friendly to the environment.

A composition containing nicotinamide mononucleotide (NMN) or an analog thereof, and certain antioxidants, more specifically resveratrol and at least one of ergothioneine and hydroxytyrosol, can be used in an anti-aging and / or anti-inflammatory method. The composition can contain NMN or nicotinamide riboside (NR) in an amount of from about 101 mg to about 1500 mg; the resveratrol in an amount of from about 50 mg to about 500 mg; ergothioneine or salt thereof, when present, in an amount of from about 3 mg to about 25 mg; and the hydroxytyrosol, when present, in an amount of from about 20 mg to about 100 mg.

Provided is a reduced β-nicotinamide mononucleotide salt-type compound as represented by formula (I), and particularly provided are a reduced β-nicotinamide mononucleotide salt and a composition thereof, a preparation method therefor, and a use thereof. The salt-type compound may serve as an active ingredient in a pharmaceutical composition for enhancing NAD+ to delay aging and / or for preventing or treating diseases or symptoms induced or caused by NAD+ deficiency and for preventing and / or treating diseases or symptoms induced or caused by deficiencies in essential elements and / or essential amino acids of the human body. In addition, compared with NMNH disodium salt crystalline and amorphous forms, the reduced β-nicotinamide mononucleotide salt-type compound exhibits long-term stability and moisture absorption resistance and is more beneficial to long-term storage and market promotion.

The present invention relates to nicotinamide mononucleotide derivatives of formula (I) for use in the treatment and / or prevention of blood disorders, in particular sickle cell disease. The invention also relates to a pharmaceutical composition comprising the compound of formula (I) for use in the treatment and / or prevention of erythrocyte disorders, in particular sickle cell disease.